resTORbio Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
March 12, 2020 07:30 ET
|
resTORbio, Inc.
BOSTON, March 12, 2020 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or...
resTORbio to Present at the 9th Annual Leerink Partners Global Healthcare Conference
February 20, 2020 08:00 ET
|
resTORbio, Inc.
BOSTON, Feb. 20, 2020 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or...
resTORbio Announces Interim Results for Phase 1b/2a Trial of RTB101 in Patients with Parkinson’s Disease and Provides Corporate Update
February 19, 2020 08:00 ET
|
resTORbio, Inc.
-- Interim data from three cohorts in the Phase 1b/2a study demonstrate that RTB101 is well tolerated, crosses the blood brain barrier, and reaches concentrations in cerebrospinal fluid observed in...
resTORbio to Present at Upcoming Investor Conferences
November 26, 2019 08:00 ET
|
resTORbio, Inc.
BOSTON, Nov. 26, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or...
resTORbio Announces That the Phase 3 PROTECTOR 1 Trial of RTB101 in Clinically Symptomatic Respiratory Illness Did Not Meet the Primary Endpoint
November 15, 2019 07:00 ET
|
resTORbio, Inc.
-- Company stops further development of clinically symptomatic respiratory illness indication but continues development of RTB101 in other aging-related diseases, including Parkinson’s disease -- --...
resTORbio Reports Third Quarter 2019 Financial Results and Corporate Update
November 05, 2019 07:00 ET
|
resTORbio, Inc.
Top-line data from PROTECTOR 1 study expected by early first quarter of 2020 RTB101 Phase 2b data demonstrating upregulation of innate antiviral immunity presented at IDWeek™ 2019 BOSTON, Nov. 05,...
resTORbio Presents New Findings on RTB101 During Late-Breaking Session at IDWeek 2019
October 02, 2019 06:00 ET
|
resTORbio, Inc.
BOSTON, Oct. 02, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc., (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or...
resTORbio to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference
September 25, 2019 08:00 ET
|
resTORbio, Inc.
BOSTON, Sept. 25, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or...
resTORbio to Present Findings on Investigational TORC1 Inhibitor RTB101 in Late-Breaking Session at IDWeek™ 2019
September 23, 2019 08:09 ET
|
resTORbio, Inc.
BOSTON, Sept. 23, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc., (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or...
resTORbio Reports Second Quarter 2019 Financial Results and Corporate Update
August 14, 2019 07:31 ET
|
resTORbio, Inc.
– Quarter highlighted by initiation and early completion of enrollment of Phase 3 PROTECTOR 1 trial; topline data expected by early first quarter of 2020 – BOSTON, Aug. 14, 2019 (GLOBE...